在胰腺癌靶區(qū)勾畫(huà)中磁共振彌散加權(quán)成像（MR-DWI）與增強(qiáng)電子計(jì)算機(jī)斷層掃描（CT）的對(duì)比研究
發(fā)布時(shí)間：2018-09-03 08:29
【摘要】：【目的】旨在進(jìn)一步研究探討胰腺癌、肝臟與區(qū)域淋巴結(jié)轉(zhuǎn)移瘤在增強(qiáng)電子計(jì)算機(jī)增強(qiáng)掃描(Computed tomography,CT)及磁共振彌散加權(quán)成像(Magnetic Resonance Diffusion Weighted Imaging,MR-DWI)上的區(qū)別,使胰腺癌放療靶區(qū)勾畫(huà)更具精確性,為指導(dǎo)臨床放療提供理論依據(jù),指導(dǎo)臨床放療實(shí)踐�！痉椒ā咳虢M患者為38例,入組條件:KPS(Karnofsky Performance Status,功能狀態(tài)評(píng)分)評(píng)分60分;未行針對(duì)胰腺癌的相關(guān)治療;患者體內(nèi)無(wú)金屬異物,可行磁共振檢查;患者對(duì)增強(qiáng)造影劑不過(guò)敏且知情并同意;經(jīng)組織病理學(xué)或者臨床確診為胰腺癌患者。所有患者均行增強(qiáng)CT及MRI定位掃描。依據(jù)不同圖像進(jìn)行逐層靶區(qū)體積勾畫(huà)(表示為:GTVCT、GTVDWI),測(cè)量腫瘤最大截面長(zhǎng)徑測(cè)量(表示為:d CT、dDWI)、肝轉(zhuǎn)移瘤(表示為:NCT肝、NMRI肝)及5-8mm、8mm淋巴結(jié)轉(zhuǎn)移瘤(表示為:NCT5-8淋巴、NMRI5-8淋巴、NCT8淋巴、NMRI8淋巴)。將相應(yīng)數(shù)據(jù)進(jìn)行統(tǒng)計(jì)分析,采用配對(duì)t檢驗(yàn)或秩和檢驗(yàn)對(duì)計(jì)量資料進(jìn)行統(tǒng)計(jì)學(xué)分析。【結(jié)果】1、患者特征:入組患者38例,男、女分別為20/18人。入組患者平均年齡59.1歲。腫瘤位于胰腺頭頸部20例,胰腺體尾部18例。19例為局部進(jìn)展期,19例伴有肝臟等轉(zhuǎn)移。行增強(qiáng)CT和MR-DWI的平均檢查間隔時(shí)間為4.3天。2、胰腺原發(fā)腫瘤比較:基于增強(qiáng)CT、MR-DWI所勾畫(huà)的腫瘤靶區(qū)體積大小,分別為54.95cm3(12.41cm3-266.29cm3)、41.67cm3(5.66cm3-235.41cm3),均值差值13.28cm3(8.26cm3-18.29cm3),使用配對(duì)wilcoxon檢驗(yàn)分析得出兩組數(shù)據(jù)有統(tǒng)計(jì)學(xué)差異。依據(jù)增強(qiáng)CT及MR-DWI所測(cè)量的腫瘤最大界面長(zhǎng)徑分別為4.18cm(1.76cm-7.3cm)、3.94cm(1.48cm-7.33cm),均值差值為0.24cm(0.18cm-0.30cm)。配對(duì)t檢驗(yàn)分析得出p0.001,結(jié)果有統(tǒng)計(jì)學(xué)差異。表明MR-DWI所測(cè)量的腫瘤靶區(qū)體積及腫瘤最大界面長(zhǎng)徑較增強(qiáng)CT小。3、胰腺癌肝臟轉(zhuǎn)移比較:有肝臟轉(zhuǎn)移患者19例,占比50%。依據(jù)增強(qiáng)CT與MR-DWI圖像分別檢出肝臟轉(zhuǎn)移瘤為83vs112枚,CT檢出只量占MR-DWI檢出量的74%,MR-DWI檢出可覆蓋全部增強(qiáng)CT檢出。經(jīng)配對(duì)wilcoxon秩和檢驗(yàn)分析得出p0.001,二者之間有顯著統(tǒng)計(jì)學(xué)差異,表明DWI對(duì)胰腺癌肝轉(zhuǎn)移有更高檢出率。4、區(qū)域淋巴結(jié)轉(zhuǎn)移比較:依據(jù)增強(qiáng)CT與MR-DWI圖像,分別檢出8mm區(qū)域淋巴結(jié)轉(zhuǎn)移者46vs56枚,增強(qiáng)CT檢出量只有MR-DWI檢出量的82%。依據(jù)增強(qiáng)CT與MR-DWI圖像分別檢出5-8mm區(qū)域淋巴結(jié)為103vs200枚,增強(qiáng)CT檢出量只有MR-DWI檢出量的52%,且MR-DWI檢出可覆蓋全部增強(qiáng)CT檢出。使用配對(duì)wilcoxon檢驗(yàn)得p值均小于0.001。N_(CT5-8淋巴)、N_(DWI5-8淋巴)與N_(CT8淋巴)、N_(DWI8淋巴)之間均有統(tǒng)計(jì)學(xué)差異,表明MR-DWI對(duì)區(qū)域淋巴結(jié)檢出有較高敏感性,但臨床診斷特異性還有待深入研究�！窘Y(jié)論】基于MR-DWI所測(cè)量的腫瘤靶區(qū)體積及腫瘤最大界面長(zhǎng)徑較增強(qiáng)CT小,肝轉(zhuǎn)移及區(qū)域淋巴結(jié)檢出較增強(qiáng)CT敏感。在制定胰腺癌放療計(jì)劃時(shí),參考MR-DWI可使得靶區(qū)邊界更加清晰,對(duì)于肝臟及區(qū)域淋巴結(jié)轉(zhuǎn)移檢出敏感性顯著高于CT檢查,有助于臨床治療方案的確定和放療計(jì)劃的修正,當(dāng)然還需要進(jìn)一步深入研究MR-DWI檢出率的特異性。參照病理的進(jìn)一步對(duì)照研究是有必要的。
[Abstract]:[Objective] To investigate the difference between enhanced computed tomography (CT) and magnetic Resonance Diffusion Weighted Imaging (MR-DWI) in pancreatic cancer, liver and regional lymph node metastases, so as to make the target area delineation more accurate and guide the clinical practice. [Methods] 38 patients with KPS (Karnofsky Performance Status) score of 60 points, no treatment for pancreatic cancer, no metallic foreign body in the body, feasible magnetic resonance imaging, and no sensitivity to contrast agents, were enrolled in the study. All patients underwent enhanced CT and MRI localization scan. The target volume was delineated layer by layer according to different images (GTVCT, GTVDWI), the maximum cross-sectional length of the tumor was measured (expressed as: D CT, dDWI), hepatic metastases (expressed as: NCT liver, NMRI liver) and lymph node metastasis of 5-8 mm, 8 mm. Tumor metastasis (expressed as NCT 5-8 lymph node, NMRI 5-8 lymph node, NCT 8 lymph node, NMRI 8 lymph node). Statistical analysis of the corresponding data was carried out by paired t test or rank sum test. [Results] 1. Patient characteristics: 38 patients in the study group, 20/18 men, women respectively. The average age of the patients in the study group was 59.1 years. The mean interval between contrast-enhanced CT and MR-DWI was 4.3 days.2. Compared with primary pancreatic tumors, the size of the tumor target area based on contrast-enhanced CT and MR-DWI was 54.95 cm 3 (12.41 cm 3-266.29 cm 3), 41.67 cm 3 (5.66 cm 3-235.41 cm 3), respectively. The maximum tumor interface length measured by enhanced CT and MR-DWI was 4.18 cm (1.76 cm-7.3 cm), 3.94 cm (1.48 cm-7.33 cm), and the mean difference was 0.24 cm (0.18 cm-0.30 cm). Compared with contrast-enhanced CT, MR-DWI showed that the tumor target volume and the maximum tumor interface length were smaller. 3. Compared with contrast-enhanced CT, 19 patients with hepatic metastasis had hepatic metastasis, accounting for 50%. According to contrast-enhanced CT and MR-DWI, 83 vs 112 hepatic metastases were detected, only 74% of them were detected by CT, and the detection of MR-DWI could cover all of them. Strong CT was detected. The paired Wilcoxon rank sum test showed that p0.001 was significantly different between the two, indicating that DWI had a higher detection rate of liver metastasis of pancreatic cancer. 4. Regional lymph node metastasis was compared. According to enhanced CT and MR-DWI images, 46 vs56 lymph node metastases were detected in 8 mm region, and only 82% of enhanced CT was detected by MR-DWI. According to contrast-enhanced CT and MR-DWI images, 103 vs 200 lymph nodes were detected in 5-8 mm region, only 52% of them were detected by contrast-enhanced CT, and the detection of MR-DWI could cover all the enhanced CT. The p value of matched Wilcoxon test was less than 0.001.N_ (CT5-8 lymph), N_ (DWI 5-8 lymph) and N_ (CT8 lymph), N_ (DWI 8 lymph) were statistically significant. The difference shows that MR-DWI is more sensitive to regional lymph node detection, but the specificity of clinical diagnosis remains to be further studied. [Conclusion] The volume of tumor target and the maximum diameter of tumor interface measured by MR-DWI are smaller than that by contrast-enhanced CT, and the detection of liver metastasis and regional lymph node is more sensitive than that by contrast-enhanced CT. WI can make the target boundary clearer, and the sensitivity of detection of liver and regional lymph node metastasis is significantly higher than that of CT. It is helpful to determine the clinical treatment plan and revise the radiotherapy plan. Of course, further study on the specificity of MR-DWI detection rate is needed.
【學(xué)位授予單位】：大連醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R445.2;R735.9
本文編號(hào)：2219438
[Abstract]:[Objective] To investigate the difference between enhanced computed tomography (CT) and magnetic Resonance Diffusion Weighted Imaging (MR-DWI) in pancreatic cancer, liver and regional lymph node metastases, so as to make the target area delineation more accurate and guide the clinical practice. [Methods] 38 patients with KPS (Karnofsky Performance Status) score of 60 points, no treatment for pancreatic cancer, no metallic foreign body in the body, feasible magnetic resonance imaging, and no sensitivity to contrast agents, were enrolled in the study. All patients underwent enhanced CT and MRI localization scan. The target volume was delineated layer by layer according to different images (GTVCT, GTVDWI), the maximum cross-sectional length of the tumor was measured (expressed as: D CT, dDWI), hepatic metastases (expressed as: NCT liver, NMRI liver) and lymph node metastasis of 5-8 mm, 8 mm. Tumor metastasis (expressed as NCT 5-8 lymph node, NMRI 5-8 lymph node, NCT 8 lymph node, NMRI 8 lymph node). Statistical analysis of the corresponding data was carried out by paired t test or rank sum test. [Results] 1. Patient characteristics: 38 patients in the study group, 20/18 men, women respectively. The average age of the patients in the study group was 59.1 years. The mean interval between contrast-enhanced CT and MR-DWI was 4.3 days.2. Compared with primary pancreatic tumors, the size of the tumor target area based on contrast-enhanced CT and MR-DWI was 54.95 cm 3 (12.41 cm 3-266.29 cm 3), 41.67 cm 3 (5.66 cm 3-235.41 cm 3), respectively. The maximum tumor interface length measured by enhanced CT and MR-DWI was 4.18 cm (1.76 cm-7.3 cm), 3.94 cm (1.48 cm-7.33 cm), and the mean difference was 0.24 cm (0.18 cm-0.30 cm). Compared with contrast-enhanced CT, MR-DWI showed that the tumor target volume and the maximum tumor interface length were smaller. 3. Compared with contrast-enhanced CT, 19 patients with hepatic metastasis had hepatic metastasis, accounting for 50%. According to contrast-enhanced CT and MR-DWI, 83 vs 112 hepatic metastases were detected, only 74% of them were detected by CT, and the detection of MR-DWI could cover all of them. Strong CT was detected. The paired Wilcoxon rank sum test showed that p0.001 was significantly different between the two, indicating that DWI had a higher detection rate of liver metastasis of pancreatic cancer. 4. Regional lymph node metastasis was compared. According to enhanced CT and MR-DWI images, 46 vs56 lymph node metastases were detected in 8 mm region, and only 82% of enhanced CT was detected by MR-DWI. According to contrast-enhanced CT and MR-DWI images, 103 vs 200 lymph nodes were detected in 5-8 mm region, only 52% of them were detected by contrast-enhanced CT, and the detection of MR-DWI could cover all the enhanced CT. The p value of matched Wilcoxon test was less than 0.001.N_ (CT5-8 lymph), N_ (DWI 5-8 lymph) and N_ (CT8 lymph), N_ (DWI 8 lymph) were statistically significant. The difference shows that MR-DWI is more sensitive to regional lymph node detection, but the specificity of clinical diagnosis remains to be further studied. [Conclusion] The volume of tumor target and the maximum diameter of tumor interface measured by MR-DWI are smaller than that by contrast-enhanced CT, and the detection of liver metastasis and regional lymph node is more sensitive than that by contrast-enhanced CT. WI can make the target boundary clearer, and the sensitivity of detection of liver and regional lymph node metastasis is significantly higher than that of CT. It is helpful to determine the clinical treatment plan and revise the radiotherapy plan. Of course, further study on the specificity of MR-DWI detection rate is needed.
【學(xué)位授予單位】：大連醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R445.2;R735.9
【參考文獻(xiàn)】
相關(guān)期刊論文 前6條
1 秦丹;王萍;時(shí)惠平;胡琪璐;周旭嘉;楊凱;;3.0T MR多b值DWI序列評(píng)價(jià)胰腺癌放療療效[J];中國(guó)醫(yī)學(xué)影像技術(shù);2015年04期
2 曾復(fù);葛春林;;胰腺癌185例診治回顧分析[J];中國(guó)普通外科雜志;2015年03期
3 郭啟勇;辛軍;張新;于兵;趙周社;李宏利;李紅;王曉明;廖偉;;MRI水?dāng)U散加權(quán)成像分子機(jī)理研究進(jìn)展[J];中國(guó)臨床醫(yī)學(xué)影像雜志;2013年07期
4 洪建平;左長(zhǎng)京;;肝臟轉(zhuǎn)移瘤影像學(xué)檢查進(jìn)展[J];實(shí)用醫(yī)學(xué)影像雜志;2013年01期
5 Ioannis Koutsounas;Constantinos Giaginis;Efstratios Patsouris;Stamatios Theocharis;;Current evidence for histone deacetylase inhibitors in pancreatic cancer[J];World Journal of Gastroenterology;2013年06期
6 李如迅;時(shí)高峰;彰俊杰;王琦;許茜;王亞寧;杜煜;;MR彌散加權(quán)成像診斷淋巴結(jié)轉(zhuǎn)移:與病理相對(duì)照[J];中國(guó)醫(yī)學(xué)影像技術(shù);2009年09期
，本文編號(hào)：2219438
本文鏈接：http://www.sikaile.net/yixuelunwen/fangshe/2219438.html
最近更新
教材專(zhuān)著
